MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Chorea (also see specific diagnoses, Huntingtons disease, etc): Treatment"

  • 2023 International Congress

    Real-world effectiveness and safety of deutetrabenazine in patients with chorea associated with Huntington disease

    V. Sung, A. White, H. Romdhani, D. Goldschmidt, R. Ayyagari, N. Chaijale, A. Yaari, M. Gordon, J. Logan, A. Yang, R. Ribalov (Birmingham, USA)

    Objective: To assess real-world effectiveness and safety of deutetrabenazine (DTBZ) for chorea associated with Huntington disease (HD). Background: Real-world evidence on the impact of DTBZ…
  • 2023 International Congress

    Treatment of chorea in pediatric subjects with pallidal and thalamic deep brain stimulation

    J. Maclean, A. Salisbury, J. Olaya, M. Liker, T. Sanger (Orange, USA)

    Objective: Assess the utility of deep brain stimulation (DBS) in treatment of chorea in pediatric patients. Background: While DBS has become common in treatment of…
  • 2023 International Congress

    AAV5-miHTT gene therapy mediates sustained mutant huntingtin lowering in brain and cerebrospinal fluid of Huntington’s disease minipigs up to 5 years

    L. Van_der Bent, C. Brouwers, A. Stam, L. Spronck, J. Klíma, J. Juhásová, B. Levinská, S. Juhás, J. Motlík, M. Evers, Z. Ellederova, A. Valles (Amsterdam, Netherlands)

    Objective: Our objective is to assess long-term safety of and durability of an adeno-associated viral vector serotype 5 encoding an engineered miRNA (AAV5-miHTT) targeting human…
  • 2023 International Congress

    Neurologic music therapy for fine motor rehabilitation in Huntington’s disease: a pilot study

    E. Forbes, L. Lattanzio, L. Quiller, L. Seeberger, I. Buard (Aurora, USA)

    Objective: To present preliminary evidence of fine motor rehabilitation in patients with Huntington’s disease using neurologic music therapy. Background: Huntington’s disease (HD) is an autosomal…
  • 2023 International Congress

    Effectiveness of deep brain stimulation in the treatment of Huntington’s disease

    H. Rodrigues, G. Mantovani, M. da Rosa, V. de Souza, L. Aires, M. Fin, L. Lobato, R. Albuquerque, PL. da Silva, A. Hilbig (Porto Alegre, Brazil)

    Objective: The aim is to obtain relevant information regarding the effectiveness of using Deep Brain Stimulation (DBS) as a treatment of Huntington's disease (HD). Background:…
  • 2023 International Congress

    Crushing valbenazine capsule contents for potential addition to soft foods or administration via G tube

    M. Hebert, A. Mar, R. Moore, A. Bristow, S. Siegert (San Diego, USA)

    Objective: To evaluate the suitability of mixing crushed contents from valbenazine capsules with soft foods/liquids or adding them to water for delivery through a gastrostomy…
  • 2023 International Congress

    Chorea improvements over time with once-daily valbenazine treatment in adults with Huntington disease

    E. Furr Stimming, E. Kayson, J. Goldstein, H. Zhang, O. Klepitskaya, G. Liang, D. Haubenberger (Houston, USA)

    Objective: To describe the effects of valbenazine (VBZ) over time on chorea in adults with Huntington disease (HD). Background: The Ph3 KINECTTM-HD (NCT04102579) trial met…
  • 2023 International Congress

    Melatonin for huntington disease (HD) gene carriers with HD-related sleep disturbance – a pilot study

    J. Patino, S. Zadegan, N. Rocha, N. Karagas, W. Tanigaki, B. Duncan, E. Furr Stimming (Houston, USA)

    Objective: To evaluate the efficacy of exogenous melatonin in improving sleep quality in Huntington disease (HD) gene carriers. Background: Various sleep disorders have been identified…
  • 2023 International Congress

    A minimal clinically important difference for UHDRS® Total Maximal Chorea score as a measure of chorea severity in Huntington disease

    E. Furr Stimming, D. Claassen, E. Kayson, J. Goldstein, H. Zhang, O. Klepitskaya, G. Liang, D. Haubenberger (Houston, USA)

    Objective: To establish a minimal clinically important difference (MCID) for the Unified Huntington Disease Rating Scale (UHDRS®) Total Maximal Chorea (TMC) score as a measure…
  • 2023 International Congress

    Metoclopramide-induced acute dystonic reaction caused by CYP2D6 *4/*4 and CYP2D6 *10/*10 genotypes

    I. šarac, H. šarac, F. Borovečki, N. Božina, I. Ivek, L. Bagarić Krakan, Z. Krešić (Zagreb, Croatia)

    Objective: Objective is to demonstrated the role of CYP P450 2D6 polymorphisms in metoclopramide-induced acute dystonic reactions. Background: Metoclopramide can induce acute extrapyramidal reactions by…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 9
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Kratom withdrawal induced orobuccal dyskinesia
  • Welcome to the MDS Abstracts Site
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Effect of Ketone Ester Supplementation on Motor and Non-Motor symptoms in Parkinson's Disease
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley